Marlene Auer
A5058427991- GDF15 and Related Biomarkers
- IL-33, ST2, and ILC Pathways
- Cancer Immunotherapy and Biomarkers
- Nuclear Receptors and Signaling
- Macrophage Migration Inhibitory Factor
- Circular RNAs in diseases
- RNA Research and Splicing
Urologische Klinik München
2022
Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved treatment1. Yet, response rates still limited, tumour progression commonly occurs2. Soluble cell-bound factors in the microenvironment negatively affect immunity. Recently, growth differentiation factor 15 (GDF-15), a cytokine that is abundantly produced by many types, was shown to interfere antitumour response. In preclinical models,...
<title>Abstract</title> Cancer immunotherapies with antibodies blocking immune checkpoint molecules are active treatments across multiple cancer entities and have markedly improved treatment. Yet, response rates still limited, tumor progression commonly occurs. Soluble cell-bound factors in the microenvironment negatively impact on immunity. Recently, Growth Differentiation-factor 15 (GDF-15), a cytokine that is abundantly produced by many types, was shown to interfere anti-tumor response....
Abstract Background: Growth and differentiation factor 15 (GDF-15), a divergent member of the TGF-β protein superfamily, shows low physiological baseline expression. GDF-15 is, however, strongly upregulated during pregnancy. It is further induced in stressed damaged tissues, where it limits immune infiltration inflammation. In solid tumors, was shown to be key inhibitor T-cell infiltration. While this might already explain strong correlation between overexpression poor survival with or...